BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Background: Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, mohair torquay for which PARP inhibitors (PARPi) are becoming a preferred treatment option.However, a considerable proportion of these carcinomas acquire resistance or harbour de novo resistance, posing a significant challenge to